目录号：MS-855
小鼠单克隆抗体（克隆号 CAS-14）
应用
* 对常规的经福尔马林处理的和石蜡包埋的组织进行免疫组化染色
* Western Blotting
* 免疫沉淀
生物学背景
p130 Cas是一种130kDa的docking蛋白，含于不同的生物学步骤中：
* Cell Adhesion
* Cell Proliferation
* Cell Migration
* Possibly Oncogenic Transformation
激素治疗乳腺癌的Tamoxifen-A
Tamoxifen（三苯氧胺），是一种选择性雌激素受体调节器（SERM）。它是目前应用最广泛的内分泌治疗法，适用于各个阶段的激素引起的乳腺癌的治疗。
尽管不能提高由雌激素受体(-)和黄体酮受体(-)引起的肿瘤的存活率，但Tamoxifen可以提高在乳癌ER(+)早期阶段的病人的无复发和完全存活率。
p130 Cas在乳腺癌中的Prognostic Value
在处于乳腺癌ER(+)早期阶段的病人体内，高p130 Cas水平与下列因素有关：
* 低无复发和完全存活率
* 疾病迅速复发
* 抗Tamoxifen的高风险性
相关产品价目表：
| 目录号 |
产品说明 |
规格
|
价格(元)
|
| MS-855P0 |
p130 Cas Ab-1(Purified Ab with BSA and Azide) |
0.1ml
|
700
|
| MS-855P1 |
p130 Cas Ab-1(Purified Ab with BSA and Azide) |
0.5ml
|
2926
|
| MS-855P |
p130 Cas Ab-1(Purified Ab with BSA and Azide) |
1ml
|
4466
|
| MS-855P1ABX |
p130 Cas Ab-1(Purified Ab without BSA and Azide) |
100μl
|
3346
|
| MS-855PABX |
p130 Cas Ab-1(Purified Ab without BSA and Azide) |
200μl
|
4886
|
| MS-855R7 |
p130 Cas Ab-1(7.0ml Ready for Histology) |
7ml
|
3206
|
| MS-855PCL |
p130 Cas Ab-1(Positive Control for Histology) |
100μl
|
980
|
| MS-855PCS |
p130 Cas Ab-1(Positive Control for Western Blot) |
5slides
|
840
|
| MS-855B0 |
p130 Cas Ab-1(Biotin-Labeled Ab with BSA and Azide) |
0.1ml
|
1400
|
| MS-855B |
p130 Cas Ab-1(Biotin-Labeled Ab with BSA and Azide) |
0.5ml
|
5726
|
| MS-855B1 |
p130 Cas Ab-1(Biotin-Labeled Ab with BSA and Azide) |
1ml
|
3766
|
| MS-855F0 |
p130 Cas Ab-1(FITC-Labeled Ab with BSA and Azide) |
0.1ml
|
1400
|
| MS-855F |
p130 Cas Ab-1(FITC-Labeled Ab with BSA and Azide) |
0.5ml
|
5726
|
| MS-855F1 |
p130 Cas Ab-1(FITC-Labeled Ab with BSA and Azide) |
1ml
|
3766
|
| MS-855PE0 |
p130 Cas Ab-1(PE-Labeled Ab with BSA and Azide) |
0.1ml
|
1400
|
| MS-855PE |
p130 Cas Ab-1(PE-Labeled Ab with BSA and Azide) |
0.5ml
|
5726
|
| MS-855PE1 |
p130 Cas Ab-1(PE-Labeled Ab with BSA and Azide) |
1ml
|
3766
|
参考文献：
1. O'Regan RM, Gradishar WJ: Selective Estrogen-Receptor Modulators in 2001. Oncology 2001 Sep; 15(9): 1178-85, 1189-90, 1190-4
2. Muss HB: Role of Adjuvant Endocrine Therapy in Early-Stage Breast Cancer. Semin Oncol 2001 Aug;28(4): 313-21
3. Brinkman A, van der Flier S, Kok EM, Dorssers LC: BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 2000 Jan 19; 92(2): 112-20
4. van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-van Gelder ME, Klijn JG, Dorssers LC, Foekens JA: Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 2000 Jan 19; 92(2): 120-7
